新冠病毒奥密克戎免疫逃逸及疫苗研究进展  

Immune Evasion and Vaccine Research Progress of SARS-CoV-2 Omicron

作　　者：马磊[1] 杨昭庆[1] 王佑春 MA Lei;YANG Zhao-qing;WANG You-chun(Institute of Medical Biology,Chinese Academy of Medical Sciences)

机构地区：[1]中国医学科学院医学生物学研究所

出　　处：《中国食品药品监管》2023年第8期24-31,共8页China Food & Drug Administration Magazine

摘　　要：在新冠病毒奥密克戎(Omicron)依然不断变异的背景下,针对Omicron变异株免疫逃逸特点选择合适的疫苗研发策略,对于诱导有效的免疫保护至关重要。与新冠疫情发生初期的新冠病毒原始毒株(SARS-CoV-2)疫苗相比,Omicron疫苗的研发不论是在基础技术平台上还是在研发策略上都取得了一些进展。本文介绍了Omicron变异株免疫逃逸机制及特点,并对目前Omicron疫苗研发新策略进行综述,为疫苗研发工作提供参考。Given the ongoing mutations of the SARS-CoV-2 Omicron variant,the appropriate vaccine research and development strategies that target Omicron's immune evasion characteristics is the key to induce effective immune protection.Compared with vaccines derived from the original SARS-CoV-2 strain at the beginning of COVID-19,progress has been made in both the foundational technological platforms and vaccine research and development strategies for Omicron vaccines.This article introduces the immune evasion mechanism and characteristics of Omicron variants,and summarizes the current new strategies for Omicron vaccine development,providing reference for vaccine development work.

关 键 词：新冠病毒 奥密克戎 免疫逃逸 疫苗 

分 类 号：R392[医药卫生—免疫学]